Allena Pharmaceuticals Inc

NASDAQ:ALNA   3:59:40 PM EDT
1.11
-0.04 (-3.48%)
Earnings Announcements

Allena Pharmaceuticals Reports Qtrly Loss Per Share $0.24

Published: 03/09/2021 12:35 GMT
Allena Pharmaceuticals Inc (ALNA) - Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update.
Allena Pharmaceuticals Inc - Reloxaliase Continues to Progress Through Ongoing Pivotal Phase 3 Urirox-2 Trial for Enteric Hyperoxaluria.
Allena Pharmaceuticals Inc - Alln-346 Poised to Enter Phase 1 Multiple-ascending Dose and Phase 2a Trials for Hyperuricemia and Gout.
Allena Pharmaceuticals Inc - Now Expect to Complete Interim Analysis in Our Urirox-2 Trial During Second Or Q3 of 2022.
Allena Pharmaceuticals Inc - Qtrly Loss per Share $0.24.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.22

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.23

More details on our Analysts Page.